Kazuyo Sasaki

Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials

Yuya Seko, Yoshio Sumida, Kazuyo Sasaki et al. · Journal of Gastroenterology · 2017 · 70 citations · Full text

Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan

Maki Goda, Tomoko Yamakura, Kazuyo Sasaki et al. · Current Medical Research and Opinion · 2017 · 31 citations · Full text

Combined effect of canagliflozin and exercise training on high-fat diet-fed mice

Kenichi Tanaka, Hirokazu Takahashi, Sayaka Katagiri et al. · American Journal of Physiology-Endocrinology and Metabolism · 2020 · 26 citations

Nutrition, Metabolic Disorder, High-fat Diet-fed Mice +21

Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan

Takashi Kadowaki, Masakazu Haneda, Hiroshi Ito et al. · Advances in Therapy · 2019 · 25 citations · Full text

Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet

Tohru Hira, Toshiki Koga, Kazuyo Sasaki et al. · Biochemical and Biophysical Research Communications · 2017 · 19 citations · Full text

Obesity, Metabolic Syndrome, Biochemistry +14